|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ALPI |
Gene summary for ALPI |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ALPI | Gene ID | 248 |
| Gene name | alkaline phosphatase, intestinal | |
| Gene Alias | IAP | |
| Cytomap | 2q37.1 | |
| Gene Type | protein-coding | GO ID | GO:0006793 | UniProtAcc | A0A024R4A2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 248 | ALPI | Pat01-B | Human | Stomach | GC | 2.73e-40 | 8.07e-01 | 0.5754 |
| 248 | ALPI | Pat03-B | Human | Stomach | GC | 1.68e-17 | 4.88e-01 | 0.3693 |
| 248 | ALPI | Pat17-B | Human | Stomach | GC | 8.40e-04 | 1.87e-01 | 0.3109 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ALPI | SNV | Missense_Mutation | rs377199045 | c.1394C>T | p.Ala465Val | p.A465V | P09923 | protein_coding | deleterious(0.01) | probably_damaging(0.974) | TCGA-AR-A0TV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ALPI | SNV | Missense_Mutation | rs377070041 | c.1063N>A | p.Asp355Asn | p.D355N | P09923 | protein_coding | tolerated(0.37) | benign(0.005) | TCGA-B6-A0WY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| ALPI | SNV | Missense_Mutation | c.1325C>T | p.Ala442Val | p.A442V | P09923 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ALPI | SNV | Missense_Mutation | c.888N>C | p.Glu296Asp | p.E296D | P09923 | protein_coding | tolerated(0.37) | benign(0.059) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
| ALPI | SNV | Missense_Mutation | novel | c.539N>A | p.Ala180Glu | p.A180E | P09923 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ALPI | SNV | Missense_Mutation | c.837G>C | p.Gln279His | p.Q279H | P09923 | protein_coding | tolerated(0.15) | benign(0) | TCGA-A6-6140-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | SD | |
| ALPI | SNV | Missense_Mutation | rs758104990 | c.1381C>T | p.Arg461Cys | p.R461C | P09923 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AA-3506-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ALPI | SNV | Missense_Mutation | rs151137290 | c.1060G>A | p.Asp354Asn | p.D354N | P09923 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ALPI | SNV | Missense_Mutation | rs151137290 | c.1060G>A | p.Asp354Asn | p.D354N | P09923 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ALPI | SNV | Missense_Mutation | novel | c.187N>A | p.Leu63Met | p.L63M | P09923 | protein_coding | tolerated(1) | benign(0.005) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 248 | ALPI | DRUGGABLE GENOME, ENZYME | TIOXOLONE | TIOXOLONE | ||
| 248 | ALPI | DRUGGABLE GENOME, ENZYME | ISOQUERCETIN | ISOQUERCETIN | ||
| 248 | ALPI | DRUGGABLE GENOME, ENZYME | NSC-353720 | CHEMBL1408276 | ||
| 248 | ALPI | DRUGGABLE GENOME, ENZYME | AG-538 | CHEMBL56393 | ||
| 248 | ALPI | DRUGGABLE GENOME, ENZYME | GNF-PF-1947 | CHEMBL585591 | ||
| 248 | ALPI | DRUGGABLE GENOME, ENZYME | HAEMATOXYLIN | HAEMATOXYLIN | ||
| 248 | ALPI | DRUGGABLE GENOME, ENZYME | CURCUMIN | CURCUMIN | ||
| 248 | ALPI | DRUGGABLE GENOME, ENZYME | 5,6,7,8,4'-PENTAHYDROXYFLAVONE | CHEMBL234338 | ||
| 248 | ALPI | DRUGGABLE GENOME, ENZYME | TERPYRIDINE | TERPYRIDINE | ||
| 248 | ALPI | DRUGGABLE GENOME, ENZYME | 2-AMINOPHENOXAZINONE | CHEMBL146710 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |